IRIS
PARENTI, Carmela
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.828
EU - Europa 3.036
AS - Asia 2.962
SA - Sud America 556
AF - Africa 527
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 5
Totale 15.925
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.560
SG - Singapore 1.363
CN - Cina 1.136
IT - Italia 1.032
IE - Irlanda 615
UA - Ucraina 536
BR - Brasile 497
CI - Costa d'Avorio 374
CA - Canada 234
DE - Germania 188
RU - Federazione Russa 188
SE - Svezia 103
SN - Senegal 103
KR - Corea 88
GB - Regno Unito 87
VN - Vietnam 72
IN - India 67
JP - Giappone 57
FR - Francia 46
FI - Finlandia 37
ES - Italia 31
PL - Polonia 29
NL - Olanda 26
BD - Bangladesh 25
BE - Belgio 25
MX - Messico 25
ID - Indonesia 24
UZ - Uzbekistan 20
HK - Hong Kong 19
AR - Argentina 18
AT - Austria 17
CH - Svizzera 17
ZA - Sudafrica 17
TR - Turchia 16
IQ - Iraq 15
CZ - Repubblica Ceca 14
GR - Grecia 11
AU - Australia 10
EC - Ecuador 10
PK - Pakistan 10
AE - Emirati Arabi Uniti 8
MA - Marocco 8
CO - Colombia 7
HU - Ungheria 7
IR - Iran 7
LB - Libano 7
VE - Venezuela 7
DZ - Algeria 6
LT - Lituania 6
PE - Perù 6
TH - Thailandia 6
BG - Bulgaria 5
CL - Cile 5
EG - Egitto 5
EU - Europa 5
IL - Israele 5
AL - Albania 4
KE - Kenya 4
NG - Nigeria 4
NO - Norvegia 4
SA - Arabia Saudita 4
AZ - Azerbaigian 3
PY - Paraguay 3
TN - Tunisia 3
BB - Barbados 2
DK - Danimarca 2
NP - Nepal 2
SV - El Salvador 2
UY - Uruguay 2
AO - Angola 1
BO - Bolivia 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
EE - Estonia 1
ET - Etiopia 1
GE - Georgia 1
GP - Guadalupe 1
HR - Croazia 1
JM - Giamaica 1
JO - Giordania 1
KZ - Kazakistan 1
LI - Liechtenstein 1
LK - Sri Lanka 1
MY - Malesia 1
NZ - Nuova Zelanda 1
OM - Oman 1
PS - Palestinian Territory 1
PT - Portogallo 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
SL - Sierra Leone 1
TL - Timor Orientale 1
TT - Trinidad e Tobago 1
Totale 15.925
Salva come PNG Salva come JPEG
Città #
Dallas 1.709
Houston 1.023
Santa Clara 1.011
Chandler 794
Singapore 700
Dublin 611
Jacksonville 513
Chicago 467
Abidjan 374
Catania 331
Ashburn 315
Boardman 289
Nanjing 190
Hefei 174
Cambridge 173
Lawrence 173
Beijing 172
Andover 171
Toronto 160
Dakar 103
Civitanova Marche 94
Wilmington 94
Los Angeles 93
Seoul 88
San Mateo 87
Bremen 83
Des Moines 71
Council Bluffs 70
Nanchang 65
Columbus 52
Shenyang 52
The Dalles 51
São Paulo 50
Tokyo 50
Saint Petersburg 46
New York 45
Jiaxing 42
Ottawa 42
Rome 42
Changsha 40
Munich 39
Tianjin 38
Hebei 34
Grafing 32
Naples 31
Brussels 24
Ho Chi Minh City 22
Moscow 19
Brooklyn 18
Jakarta 18
Seattle 18
Turku 18
Warsaw 18
Dong Ket 17
Falls Church 17
Pune 17
Rio de Janeiro 17
Buffalo 16
Denver 16
Hong Kong 16
Messina 16
Atlanta 15
Hanoi 15
Jinan 15
Montreal 15
Ningbo 15
Norwalk 15
San Giovanni la Punta 14
Augusta 13
Belo Horizonte 13
Helsinki 13
Washington 13
Johannesburg 12
Mascalucia 11
Zhengzhou 11
Campinas 10
London 10
Milan 10
Orem 10
Paternò 10
Phoenix 10
San Francisco 10
Amsterdam 9
Boston 9
Kunming 9
Leawood 9
Madrid 9
Salerno 9
Salvador 9
Ann Arbor 8
Chennai 8
Fremont 8
Fuzhou 8
Liberty Lake 8
Mumbai 8
Palermo 8
Porto Alegre 8
Stockholm 8
Tappahannock 8
Tashkent 8
Totale 11.582
Salva come PNG Salva come JPEG
Nome #
Wilms' tumor gene 1 silencing inhibits proliferation of human osteosarcoma MG-63 cell line by cell cycle arrest and apoptosis activation. 434
Simultaneous targeting of MOR/DOR: A useful strategy for inflammatory pain modulation 393
NOP RECEPTOR ANTAGONISM IN THE VENTROLATERAL PERIAQUEDUCTAL GRAY ATTENUATES THE DEVELOPMENT OF OPIOID TOLERANCE. 315
((2S)-N-2-methoxy-2-phenylethyl-6,7-benzomorphan compound (2S-LP2): Discovery of a biased mu/delta opioid receptor agonist 269
The simultaneous activation of μ- and δ-opioid receptors by (−)-2S-LP2 rescues allodynia with the contribution of TGF-β1 signaling in a rat chronic constriction injury model 195
Involvement of sigma 2 receptor on motor disorder 186
Do vitamins halt the COVID-19-evoked pro-inflammatory cytokines involved in the development of neuropathic pain? 169
Neuroprotective effects of Rosmarinus officinalis L. extract in oxygen glucose deprivation (OGD)-injured human neural-like cells 167
Design, synthesis, in vitro evaluation, and molecular modeling studies of N-substituted benzomorphans, analogs of LP2, as novel MOR ligands 155
Inhibition of Cx43 mediates protective effects on hypoxic/reoxygenated human neuroblastoma cells 144
Benzomorphan skeleton, a versatile scaffold for different targets: A comprehensive review 136
(+)-and (−)-Phenazocine enantiomers: evaluation of their dual opioid agonist/σ1 antagonist properties and antinociceptive effects 134
Development of a Sigma-2 Receptor affinity filter through a Monte Carlo based QSAR analysis 134
Influenza del N-sostituente della (–)-cis-N-Normetazocina nella modulazione del profilo funzionale al MOR, DOR e KOR: da agonista ad antagonista attraverso ligandi misti agonisti/antagonisti 133
A new Sigma-1 Receptor antagonist in Chronic Pain Treatment: (+)-2R/S-LP2 effects in inflammatory and neuropathic pain 128
A new sigma ligand, (+/-)-PPCC, antagonizes kappa opioid receptor-mediated antinociceptive effect 122
Exploiting the Power of Stereochemistry in Drug Action: 3-[(2S,6S,11S)-8-Hydroxy-6,11-dimethyl-1,4,5,6-tetrahydro-2,6-methano-3-benzazocin-3(2H)-yl]-N-phenylpropanamide as Potent Sigma-1 Receptor Antagonist 122
R- ed S-LP2: sintesi, molecular docking e valutazione farmacologica 120
CHF5074 protects SH-SY5Y human neuronal-like cells from amyloidbeta 25-35 and tumor necrosis factor related apoptosis inducing ligand toxicity in vitro 119
Connexins in the central nervous system: physiological traits and neuroprotective targets 119
Novel N-Substituted Benzomorphan-Based Compounds: From MOR-Agonist/DOR-Antagonist to Biased/Unbiased MOR Agonists 117
ANTIALLODINIC AND ANTIHYPERALGESIC EFFECTS OF LP1, AN OPIOID MULTITARGET LIGAND, IN INFLAMMATORY AND NEUROPATHIC PAIN STATES 115
Benzomorphan scaffold for opioid analgesics and pharmacological tools development: A comprehensive review 115
Antinociceptive profile of LP1, a non-peptide multitarget opioid ligand. 109
Synthesis, in vitro and in vivo characterization of new benzoxazole and benzothiazole-based sigma receptor ligands 109
The Multimodal MOPr/DOPr Agonist LP2 Reduces Allodynia in Chronic Constriction Injured Rats by Rescue of TGF-β1 Signalling 108
LP2 e 2S-LP2: agonisti biased dual target MOR/DOR nel trattamento del dolore cronico 107
Sigma-2 receptor ligands QSAR model dataset 105
Lipid Nanoparticle Inclusion Prevents Capsaicin-Induced TRPV1 Defunctionalization 105
Intercellular communication and ion channels in neuropathic pain chronicization 105
Synthesis and Structure-Activity Relationships of LP1 Derivatives: N-Methyl-N-phenylethylamino Analogues as Novel MOR Agonists 104
From plant to bench: natural products as source for analgesic drug development. 104
Central and peripheral control by endogenous opioid peptides of gastric protection in stressed-rats 103
Studio aerobiologico e incidenza di pollinosi nella popolazione acese 102
Development of novel LP1-based analogues with enhanced delta opioid receptor profile 101
Chronic treatment with fluoxetine induces sex-dependent analgesic effects and modulates HDAC2 and mGlu2 expression in female mice 101
In Vitro Antioxidant Activity and In Vivo Topical Efficacy of Lipid Nanoparticles Co-Loading Idebenone and Tocopheryl Acetate 101
Sigma-1 Receptor Inhibition Reduces Mechanical Allodynia and Modulate Neuroinflammation in Chronic Neuropathic Pain 100
Dual MOR/DOR agonist benzomorphan-based compounds for pain relief 100
Effect of supraspinal Nocistatin on nociceptin/OrphaninFQ antagonism of selective opioid analgesia 99
Activity of profens as racemic (R and S) enantiomers in human condrocytes and cartilage 98
Design, synthesis, and biological evaluation of new hybrid MOR agonist/HDACi compounds: an innovative approach for persistent pain management 96
Blockade of the nociceptin/orphanin FQ/NOP receptor system in the rat ventrolateral periaqueductal gray potentiates DAMGO analgesia 96
MOR/DOR targeting: an useful strategy in pain management 96
The antagonistic effect of the sigma 1 receptor ligand (+)-MR200 on persistent pain induced by inflammation. 95
(+)-Mr200 derivatives: modifications on the amino moiety. In vitro and in vivo pharmacological evaluation 95
Apoptotic effects of (±) MRJF4 in prostate cancer cells 95
Mu and Delta Opioid Receptor Targeting Reduces Connexin 43-Based Heterocellular Coupling during Neuropathic Pain 93
The benzomorphan-based LP1 ligand is a suitable MOR/DOR agonist for chronic pain treatment 93
Activity of profens as racemic (R and S) enantiomers in human condrocytes and cartilage 93
Tumor necrosis factor-related apoptosis-inducing ligand reduces the expression of the neuroprotective Na+ /Ca2+ exchanger isoform NCX3 in human neuroblastoma SH-SY5Y cells 93
Effect of CCK-8 on analgesia induced by cold-restraint stress in the rat 92
Wilms’ Tumor Gene 1 (WT1) silencing inhibits proliferation of malignant peripheral nerve sheath tumor sNF96.2 cell line 92
Neuroprotective effect of the new sigma receptor ligands cis-(+) and cis-(–)-PPCC 92
A New LP1 analogue is used to better understand MOR ligand Binding Domain and its mechanisms of activation 92
Simultaneous Activation of Mu and Delta Opioid Receptors Reduces Allodynia and Astrocytic Connexin 43 in an Animal Model of Neuropathic Pain 92
Multitarget opioid ligands in pain relief: New players in an old game 91
An LP1 analogue, selective MOR agonist with a peculiar pharmacological profile, used to scrutiny the ligand binding domain 91
Ischemic tolerance modulates TRAIL expression and its receptors and generates a neuroprotected phenotype 90
Antiallodinic and antihyperalgesic effects of LP1, an opioid multitarget ligand, in inflammatory and neurophatic pain states 90
Novel Sigma-1 receptor antagonists: From opioids to small molecules: What is new? 90
The benzomorphan-based compound LP1 is a central acting MOR agonist/DOR antagonist suitable for chronic pain treatment 89
Effects of dinorphin 1-13 on hyperalgesia induced by interleukin-1bera in the rat 88
Preclinical evidence of enhanced analgesic activity of duloxetine complexed with succinyl-β-cyclodextrin: A comparative study with cyclodextrin complexes 88
Prevention of stress-induced gastric ulcers by mu- and delta-opioid agonists in the rat. 87
Involvement of the Heme-Oxygenase Pathway in the Antiallodynic and Antihyperalgesic Activity of Harpagophytum procumbens in Rats. 87
ANTIALLODYNIC AND ANTIHYPERALGESIC EFFECTS OF INTRAPLANTAR NOCISTATIN AND (±)-J 113397 IN INFLAMMATORY PAIN 87
Multitarget Opioid/Non-opioid Ligands: A Potential Approach in Pain Management 87
Evaluation of N-substituent structural variations in opioid receptor profile of LP1. 87
The Benzomorphan-Based Compound LP1 as Suitable Candidate for Pain Management 86
Repeated activation of delta opiod receptors counteracts nerve injury-induced TNF-α up-regulation in the sciatic nerve of rats with neuropathic pain: A possible correlation with delta opiod receptors-mediated antiallodinic effect. 85
Discovery of first novel sigma/HDACi dual-ligands with a potent in vitro antiproliferative activity 83
New Insights into the Opioid Analgesic Profile of cis-(-)-N-Normetazocine-derived Ligands 83
Wilms' tumor 1 (WT1) protein expression in human developing tissues 83
Central and peripheral involvement of endogenous opioid peptides in gastric protection in stressed rats 83
Scouting new sigma receptor ligands: Synthesis, pharmacological evaluation and molecular modeling of 1,3-dioxolane-based structures and derivatives 83
Progress in the development of more effective and safer analgesics for pain management 83
Antiallodynic and antihyperalgesic effects of intraplantar nocistatin and (+/-)-J113397 in inflammatory pain 81
Novel N-normetazocine Derivatives with Opioid Agonist/Sigma-1 Receptor Antagonist Profile as Potential Analgesics in Inflammatory Pain 80
In vitro and in vivo pharmacological evaluation of LP1, a benzomorphan-based compound 80
Rosemary Essential Oil-Loaded Lipid Nanoparticles: In Vivo Topical Activity from Gel Vehicles 80
Effects of a Selective Sigma 1 Antagonist Compound on Inflammatory Pain 80
Effect of centrally administered -B-endorphin on the development of stress-induced gastric ulcers in rats 79
Rescue of noradrenergic system as a novel pharmacological strategy in the treatment of chronic pain: Focus on microglia activation 79
In-vitro evaluation of a new benzomorphan-based ligand 78
The multitarget opioid ligand LP1's effects in persistent pain and in primary cell neuronal cultures 78
Synthesis and in vitro opioid receptor studies on benzomorphan-based compounds: LP1, a potent and long-acting antinociceptive 77
Different in vitro activity of flurbiprofen and its enantimers on human articular cartilage 77
Dual-target ligands and pain: our experience 76
Stress-induced changes in the thermic effects of cholecystokinin in the rat 76
HDAC and HAT inhibitors differently affect analgesia mediated by group II metabotropic glutamate receptors 76
Involvement of the Nociceptin/Orphanin FQ-NOP receptor system in the ventrolateral periaqueductal gray following mechanical allodynia in chronic pain 76
THE BENZOMORPHAN-BASED COMPOUND LP1 AS A MULTITARGET OPIOID LIGAND FOR CHRONIC PAIN TREATMENT 76
Role of the Nrf2/HO-1 axis in bronchopulmonary dysplasia and hyperoxic lung injuries 76
Supraspinal injection of Substance P attenuates allodynia and hyperalgesia in a rat model of inflammatory pain 75
Hybrid MOR agonist/HDACi molecules as potential antinociceptive multi-target drugs: design, synthesis, and biological evaluation 74
From Plant to Chemistry: Sources of Antinociceptive Non-Opioid Active Principles for Medicinal Chemistry and Drug Design 74
Inhibition of pain response in the formalin test by naloxone in normal- or cold-.restrained-rats 74
Synthesis and structure-activity relationships of (–)-cis-N-normetazocine-based LP1 derivatives 74
Synthesis, Computational Insights, and Evaluation of Novel Sigma Receptors Ligands 73
Totale 10.897
Salva come PNG Salva come JPEG
Categoria #
all - tutte 54.047
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 54.047
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021812 0 0 0 0 294 35 106 8 110 16 170 73
2021/20221.382 163 178 15 38 210 16 186 56 123 23 56 318
2022/20232.419 196 127 46 291 214 378 8 439 512 45 101 62
2023/20241.265 82 218 78 62 68 286 48 76 2 33 218 94
2024/20254.084 67 747 214 236 877 480 196 188 243 321 243 272
2025/20263.627 527 340 1.908 455 397 0 0 0 0 0 0 0
Totale 16.367